Latest Kidney Cancer News
Kidney Cancer News elsewhere on the Web
“Taken altogether, the study remains positive for PFS, but not for overall survival,” says Laurence Albiges, MD, PhD.
“Over 80% of patients…had at least 2 lines of therapy, so this is a heavily refractory population,” said Toni K. Choueiri, MD, FASCO.
Studied in combination with Opdivo, Cabometyx saw RCC patients surviving 11 months longer than sunitinib patients.
Opdivo-Qvantig had a non-inferior objective response rate compared to intravenous formulation in patients with locally advanced or metastatic clear cell renal cell carcinoma. About 8.1% of patients treated with Opdivo-Qvantig experienced a transient, local injection-site reaction. The Latest ...
Axel Merseburger, MD, PhD, discusses the real-world efficacy and safety of first-line avelumab plus axitinib in advanced renal cell carcinoma.
The TiNivo-2 trial found comparable PROs with tivozanib plus nivolumab vs tivozanib monotherapy in advanced clear cell RCC.
Clear cell renal cell carcinoma (ccRCC) exhibits considerable heterogeneity, with approximately 25% of localized cases susceptible to relapse, highlighting the challenge of the absence of reliable predictive biomarkers for personalized treatment. Meanwhile, metastatic renal cell carcinoma is ...
Clear cell renal cell carcinoma (ccRCC) exhibits considerable heterogeneity, with approximately 25% of localized cases susceptible to relapse, highlighting the challenge of the absence of reliable predictive biomarkers for personalized treatment. Meanwhile, metastatic renal cell carcinoma is ...
Investigators from Shanghai, China, report responses above 90% by using levantinib and tislelizumab to treat patients with a form of renal cell carcinoma (RCC) driven by a mostly inherited mutation.
Patient-reported outcomes were similar for Fotivda with or without Opdivo in advanced clear cell RCC.
No results found.
Articles from Kidney Cancer UK
No results found.
No results found.